Worldwide, the stigma of medical cannabis treatments has subsided dramatically, with various nations embracing the extremely versatile plant for medical purposes.
One recent study, which collected and assessed patient data over a period of three years, found that cannabis was the most successful treatment available for pain, spasticity, and anorexia.
It is vital that this treatment is decided by a practitioner who knows the patient and their history – a qualified pharmacist should distribute cannabis-based medicines; everything should be in a medical setting – but there is also a need for financial reimbursement.
There is a very famous quote from Paracelsus, the 16th-century physician and philosopher, saying: ‘All things are poison, and nothing is without poison; the dosage alone makes it, so a thing is not a poison.’ There is a substantial difference between treating a patient with a high level of THC for chronic pain or in palliative care and using medicines with a higher proportion of CBD and low THC to treat less serious cosmetic problems in a healthy consumer.
They fight for it, which is mirrored in their healthcare regulations and their regulatory activities, not only in making cannabis available to patients but also in the provisions they make for entrepreneurs and producers.